Multiple Sclerosis – Page 2

FDA Approves Ocrevus Zunovo: A Breakthrough Subcutaneous Injection for Multiple Sclerosis

1 year ago talkbio0Tagged Approved, drug delivery technology, ENHANZE, Halozyme, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Ocrevus Zunovo, PPMS, Progressive, Relapsing Multiple Sclerosis, RMS, Subcutaneous Injections, United States Food and Drug Administration

Ocrevus Zunovo, FDA Approval, Subcutaneous Injection, Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Primary Progressive Multiple Sclerosis (PPMS), Halozyme Therapeutics, ENHANZE drug delivery technology.

Roche’s Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Phase II Trial

1 year ago talkbio0Tagged BTK Inhibitor, Clinical Research, fenebrutinib, FENopta, Multiple Sclerosis, Phase 2 Clinical Trials, Roche (company)

Roche, fenebrutinib, relapsing multiple sclerosis, BTK inhibitor, Phase II trial, FENopta study

Sanofi’s Tolebrutinib Shows Mixed Results in Phase 3 MS Trials, Plans for FDA Filing Remain

1 year ago talkbio0Tagged File (record), Multiple Sclerosis, Phase 3 trials, sanofi, Tolebrutinib, United States Food and Drug Administration

Tolebrutinib, Sanofi, Multiple Sclerosis, Phase 3 Trials, FDA Filing

Sanofi’s Tolebrutinib Shows Mixed Results in Multiple Sclerosis Trials

1 year ago talkbio0Tagged BTK gene, Clinical Trials, Inhibitor, Multiple Sclerosis, sanofi, Tolebrutinib

Sanofi, Tolebrutinib, Multiple Sclerosis, BTK Inhibitor, Clinical Trials

Biogen Faces Lawsuit Over Alleged Kickback Scheme to Block Generic Competition for Multiple Sclerosis Drug Tecfidera

1 year ago talkbio0Tagged Biogen, generics, Multiple Sclerosis, Pharmacy Benefit Manager, Tecfidera

Biogen, kickback scheme, Tecfidera, generics, multiple sclerosis, PBM, lawsuit

Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment

1 year ago talkbio0Tagged Biotechnology, Clinical Trials, Mississippi (geographic location), Multiple Sclerosis, nervous system repair, Neurodegenerative Disorders, Progentos, Remyelination

Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.

Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis

2 years ago talkbio0Tagged Clinical, Lesion, Magnetic Resonance Imaging, Multiple Sclerosis, Multiple Sclerosis, Ocrevus, Relapse, Roche (company)

Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures

“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”

2 years ago talkbio0Tagged Biological Factors, Continuum, Demyelinating Diseases, IPO, Johnson & Johnson, LPAR1 antagonist, LPAR1 gene, Multiple Sclerosis, Neuroinflammation, PIPE-791, Public Offering, Receptors, Lysophosphatidic Acid

Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist

Contineum Launches IPO Campaign to Accelerate Multiple Sclerosis Pipeline

2 years ago talkbio0Tagged Backed, Contineum, IPO, Johnson and Johnson, Multiple Sclerosis, Phase 2 Clinical Trials, PIPE-307, Public Offering

Contineum Therapeutics, Initial Public Offering (IPO), Johnson & Johnson (J&J) Backed, Multiple Sclerosis (MS) Pipeline, Phase II Trial, PIPE-307

Merck KGaA Abandons Evobrutinib Development, Emphasizes Deal-Focused Pipeline Strategy

2 years ago talkbio0Tagged BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, evobrutinib, Failed, Merck KGaA, Multiple Sclerosis, Phase 3 trials

Merck KGaA, Evobrutinib, BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, Failed Phase 3 Trials, Multiple Sclerosis (MS) Treatment